ALG5 (Gene)

Organism:

Homo sapiens

Synonyms:ALG5 dolichyl-phosphate beta-glucosyltransferase, ALG5, ENTREZ:29880, HGNC:20266, MIM:604565, NM_001142364, NM_013338, NP_001135836, NP_037470, XM_017020552, XP_016876041, XR_001749540, bA421P11.2

Omim:OMIM:604565

Id:ENSG00000120697

Hgnc:HGNC:20266

Entrez:29880

Ensembl:ENSG00000120697

Description:ALG5 dolichyl-phosphate beta-glucosyltransferase

This gene encodes a member of the glycosyltransferase 2 family. The encoded protein participates in glucosylation of the oligomannose core in N-linked glycosylation of proteins. The addition of glucose residues to the oligomannose core is necessary to ensure substrate recognition, and therefore, effectual transfer of the oligomannose core to the nascent glycoproteins. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ALG5's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ALG5.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ALG5.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ALG5.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ALG5.

Results found

Linked to

	Label	Description
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE120370 0 V 6 THROMBIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 0 V 10 SULFORAPHANE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 3 V 0 TEMOZOLOMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE234647 1 V 3 REGORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE104022 1 V 0 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

GSE216043 7 V 9 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE120370 0 V 6 THROMBIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 0 V 10 SULFORAPHANE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE225869 3 V 0 TEMOZOLOMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE234647 1 V 3 REGORAFENIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE104022 1 V 0 TAMOXIFEN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.